Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELDN NASDAQ:GANX NASDAQ:INDP NASDAQ:NMRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELDNEledon Pharmaceuticals$3.84-4.5%$3.80$1.35▼$4.60$310.30M0.951.85 million shs757,356 shsGANXGain Therapeutics$1.66-1.2%$1.79$1.41▼$4.34$71.66M0.151.40 million shs840,381 shsINDPIndaptus Therapeutics$2.53-10.3%$2.56$0.92▼$12.23$319.34M1.11110,496 shs36,076 shsNMRANeumora Therapeutics$1.60-1.8%$1.69$0.83▼$3.65$302.01M2.741.86 million shs632,040 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELDNEledon Pharmaceuticals-4.48%-7.02%+10.34%-3.52%+1.59%GANXGain Therapeutics-1.19%-8.79%-7.26%-22.07%+2.47%INDPIndaptus Therapeutics-10.28%+1.20%-31.99%-26.67%-78.26%NMRANeumora Therapeutics-1.84%-3.03%+2.56%-25.58%+14.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELDNEledon Pharmaceuticals$3.84-4.5%$3.80$1.35▼$4.60$310.30M0.951.85 million shs757,356 shsGANXGain Therapeutics$1.66-1.2%$1.79$1.41▼$4.34$71.66M0.151.40 million shs840,381 shsINDPIndaptus Therapeutics$2.53-10.3%$2.56$0.92▼$12.23$319.34M1.11110,496 shs36,076 shsNMRANeumora Therapeutics$1.60-1.8%$1.69$0.83▼$3.65$302.01M2.741.86 million shs632,040 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELDNEledon Pharmaceuticals-4.48%-7.02%+10.34%-3.52%+1.59%GANXGain Therapeutics-1.19%-8.79%-7.26%-22.07%+2.47%INDPIndaptus Therapeutics-10.28%+1.20%-31.99%-26.67%-78.26%NMRANeumora Therapeutics-1.84%-3.03%+2.56%-25.58%+14.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELDNEledon Pharmaceuticals 2.40Hold$9.67151.74% UpsideGANXGain Therapeutics 2.67Moderate Buy$7.50351.81% UpsideINDPIndaptus Therapeutics 1.00SellN/AN/ANMRANeumora Therapeutics 2.60Moderate Buy$6.57310.71% UpsideCurrent Analyst Ratings BreakdownLatest GANX, ELDN, INDP, and NMRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/13/2026NMRANeumora Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$7.00 ➝ $5.007/1/2026GANXGain Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.006/30/2026GANXGain Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.006/24/2026ELDNEledon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/18/2026NMRANeumora Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$6.00 ➝ $4.006/16/2026NMRANeumora Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $7.006/16/2026NMRANeumora Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $5.006/9/2026GANXGain Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/27/2026GANXGain Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/12/2026GANXGain Therapeutics Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/21/2026INDPIndaptus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELDNEledon PharmaceuticalsN/AN/AN/AN/A$1.35 per shareN/AGANXGain Therapeutics$50K1,415.98N/AN/A$0.48 per share3.46INDPIndaptus TherapeuticsN/AN/AN/AN/A$1.40 per shareN/ANMRANeumora TherapeuticsN/AN/AN/AN/A$0.62 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELDNEledon Pharmaceuticals-$45.62M-$0.77N/AN/AN/AN/A-116.97%-41.91%8/13/2026 (Estimated)GANXGain Therapeutics-$20.16M-$0.58N/AN/AN/AN/A-201.44%-136.24%8/11/2026 (Estimated)INDPIndaptus Therapeutics-$20.85M-$15.40N/AN/AN/AN/A-1,030.07%-299.69%8/17/2026 (Estimated)NMRANeumora Therapeutics-$236.93M-$1.33N/AN/AN/AN/A-181.70%-119.15%8/5/2026 (Estimated)Latest GANX, ELDN, INDP, and NMRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026ELDNEledon Pharmaceuticals-$0.19N/AN/AN/AN/AN/A8/11/2026Q2 2026GANXGain Therapeutics-$0.14N/AN/AN/A$0.03 millionN/A8/5/2026Q2 2026NMRANeumora Therapeutics-$0.23N/AN/AN/AN/AN/A5/15/2026Q1 2026INDPIndaptus Therapeutics-$1.87-$0.23+$1.64-$0.23N/AN/A5/13/2026Q1 2026ELDNEledon Pharmaceuticals-$0.22-$0.33-$0.11-$0.33N/AN/A5/11/2026Q1 2026GANXGain Therapeutics-$0.13-$0.13N/A-$0.13$0.03 millionN/A5/7/2026Q1 2026NMRANeumora Therapeutics-$0.32-$0.30+$0.02-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELDNEledon PharmaceuticalsN/A8.448.44GANXGain Therapeutics0.024.694.69INDPIndaptus TherapeuticsN/A2.342.34NMRANeumora Therapeutics0.755.095.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELDNEledon Pharmaceuticals56.77%GANXGain Therapeutics11.97%INDPIndaptus Therapeutics7.06%NMRANeumora Therapeutics47.65%Insider OwnershipCompanyInsider OwnershipELDNEledon Pharmaceuticals9.60%GANXGain Therapeutics4.15%INDPIndaptus Therapeutics23.60%NMRANeumora Therapeutics26.94%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELDNEledon Pharmaceuticals1077.19 million69.78 millionOptionableGANXGain Therapeutics2042.65 million40.88 millionOptionableINDPIndaptus Therapeutics6113.24 million86.52 millionNot OptionableNMRANeumora Therapeutics108185.28 million135.37 millionOptionableGANX, ELDN, INDP, and NMRA HeadlinesRecent News About These CompaniesNeumora Therapeutics Target of Unusually Large Options Trading (NASDAQ:NMRA)July 16 at 12:19 PM | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Price Target Cut to $5.00 by Analysts at Royal Bank Of CanadaJuly 13, 2026 | marketbeat.comNeumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant DiscontinuationJuly 11, 2026 | finance.yahoo.comWhy Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to BuyJuly 7, 2026 | finance.yahoo.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Moderate Buy" by AnalystsJuly 6, 2026 | americanbankingnews.comWhy Neumora Therapeutics, Inc.’s (NMRA) Stock Is Down 9.94%June 18, 2026 | aaii.comANMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities FraudJune 18, 2026 | businesswire.comWhy Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression DataJune 17, 2026 | insidermonkey.comThree pivotal MDD trial failures for Neumora lead to staffing cutsJune 17, 2026 | finance.yahoo.comNeumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)June 16, 2026 | prnewswire.comNeumora Stock Plunges 49% After Late-Stage Depression Drug FailureJune 16, 2026 | zacks.comNeumora bins depression drug after Phase III failuresJune 16, 2026 | thepharmaletter.comTNeumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studiesJune 15, 2026 | fiercebiotech.comFNMRA stock on track for worst day in 1.5 years — Neumora Therapeutics' lead depression drug fails late stage trialsJune 15, 2026 | msn.comPenny Stock Neumora Therapeutics Cuts Workforce After Depression Trials FailJune 15, 2026 | benzinga.comNMRA INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Neumora Therapeutics, Inc.June 15, 2026 | globenewswire.comNeumora Therapeutics scraps depression drug after two late-stage trial failuresJune 15, 2026 | reuters.comNeumora ends depression drug programme and announces workforce reduction (NMRA)June 15, 2026 | msn.comNeumora Ends Navacaprant After Phase 3 Trial FailureJune 15, 2026 | tipranks.comNeumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline UpdateJune 15, 2026 | globenewswire.comNeumora Shareholders Approve Directors, Auditor and Executive PayMay 29, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGANX, ELDN, INDP, and NMRA Company DescriptionsEledon Pharmaceuticals NASDAQ:ELDN$3.84 -0.18 (-4.48%) Closing price 07/16/2026 04:00 PM EasternExtended Trading$3.87 +0.03 (+0.78%) As of 07/16/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Gain Therapeutics NASDAQ:GANX$1.66 -0.02 (-1.19%) Closing price 07/16/2026 04:00 PM EasternExtended Trading$1.66 +0.01 (+0.30%) As of 07/16/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Indaptus Therapeutics NASDAQ:INDP$2.53 -0.29 (-10.28%) Closing price 07/16/2026 04:00 PM EasternExtended Trading$2.48 -0.05 (-1.98%) As of 07/16/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.Neumora Therapeutics NASDAQ:NMRA$1.60 -0.03 (-1.84%) Closing price 07/16/2026 04:00 PM EasternExtended Trading$1.60 +0.00 (+0.31%) As of 07/16/2026 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Revving Up Returns: Big Banks Race Through the Rate Plateau Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase Japan’s Crypto Overhaul Could Open the Door to a Wave of Institutional Money AI’s Power Crunch Fuels a Pivot for These 2 Oilfield Stocks PayPal Stock Surges on $53 Billion Stripe-Advent Buyout Bid Toast’s Comeback Story Is Getting Harder for Wall Street to Ignore Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
